Fig. 2: In-depth analysis of the prognostic and predictive impact of dual KRAS and TP53 mutation. | British Journal of Cancer

Fig. 2: In-depth analysis of the prognostic and predictive impact of dual KRAS and TP53 mutation.

From: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma

Fig. 2

a Subgroups analysis of HD-ICI confirming longer OS after ICI in most of the analysed subgroups. b Longer OS in the study cohort (HD-ICI) and two external cohorts (SU2C-ICI and MSK-ICI) of patients treated with ICI. By contrast, no prolongation of survival was observed in two external cohorts (TCGA-LUAD and MSK-LUAD) of conventionally treated patients.

Back to article page